Related Experiment Video

Updated: Jul 4, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

The selectivity of inhibitors of protein kinase CK2: an update

Mario A Pagano1, Jenny Bain, Zygmunt Kazimierczuk

  • 1Department of Biological Chemistry and CNR Institute of Neurosciences, University of Padova, viale G. Colombo 3, 35131 Padova, Italy.

The Biochemical Journal
|July 1, 2008
PubMed

Insights

The study reveals that common CK2 inhibitors like DMAT are not specific and inhibit other kinases. New compounds, K64 and K66, show improved selectivity for CK2, acting as effective apoptosis inducers.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Casein kinase 2 (CK2) is a pleiotropic enzyme implicated in neoplasia.
  • Existing CK2 inhibitors, TBB and DMAT, are widely used but their specificity is questioned.

Purpose of the Study:

  • To evaluate the kinase inhibition profiles of TBB and DMAT.
  • To identify novel CK2 inhibitors with improved selectivity.

Main Methods:

  • Screening of approximately 80 protein kinases against DMAT, TBB, and related compounds.
  • Testing a library of 68 TBB/TBI-related compounds for selectivity against CK2, PIM1, HIPK2, and DYRK1a.
  • Assessing apoptosis-inducing efficacy of novel compounds.

Main Results:

  • DMAT and TBI inhibit multiple kinases including PIM1, PIM2, PIM3, PKD1, HIPK2, and DYRK1a.
  • TBB demonstrates higher selectivity for CK2 but also inhibits PIM1 and PIM3.
  • Seven novel compounds showed enhanced CK2 efficacy over other kinases, with K64 and K66 exhibiting superior selectivity and apoptosis-inducing effects compared to TBB and DMAT.

Conclusions:

  • DMAT and TBI lack specificity, inhibiting a range of kinases beyond CK2.
  • Novel compounds K64 and K66 represent promising, highly selective CK2 inhibitors.
  • These new inhibitors hold potential for cancer therapy due to their apoptosis-inducing properties.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...